Muscle-Specific Regulatory Elements Enhance Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for muscle-directed therapies, such as treating Pompe disease, face challenges including inefficient gene delivery, transient transgene expression, and immune responses due to high vector doses, leading to toxicity and inadequate muscle-specific expression.
Innovation Solution
A novel combination of transcriptional cis-regulatory modules (CREs) is developed, comprising diaphragm-specific and cardiac/skeletal muscle-specific nucleic acid regulatory elements, in conjunction with a potent muscle-specific promoter, to enhance gene expression in skeletal muscle, heart, and diaphragm, allowing for lower and safer vector doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high vector doses are used to achieve desirable therapeutic effect, then gene expression level is improved, but toxicity and immune responses increase
Solution Approach 1:
The patent applies local quality by using tissue-specific regulatory elements (diaphragm-specific element and cardiac/skeletal muscle-specific element) to direct gene expression specifically to muscle tissues. This ensures high gene expression levels are achieved locally in the target muscles without requiring high vector doses systemically, thereby reducing toxicity and immune responses in non-target tissues.
Solution Approach 2:
The patent changes the parameter of vector dose by optimizing the combination of regulatory elements to achieve efficient gene expression at lower vector doses. The specific combination of diaphragm-specific element (SEQ ID NO: 1) and cardiac/skeletal muscle-specific element (SEQ ID NO: 2) with a muscle-specific promoter enables effective expression at reduced doses, directly addressing the toxicity issue associated with high dosing.
2Reliability
If conventional vectors are used to deliver therapeutic genes to muscle, then gene delivery is achieved, but transgene expression is transient and insufficient
Solution Approach 1:
The patent applies preliminary action by incorporating optimized regulatory elements (diaphragm-specific element SEQ ID NO: 1 and cardiac/skeletal muscle-specific element SEQ ID NO: 2) into the vector design before delivery. These elements pre-establish strong, sustained transcriptional activation in muscle tissues, ensuring that once the vector delivers the transgene, expression is both robust and long-lasting rather than transient.
Solution Approach 2:
The patent uses a composite regulatory structure combining two specific regulatory elements (SEQ ID NO: 1 and SEQ ID NO: 2) with a muscle-specific promoter. This composite approach creates a synergistic effect that enhances both the strength and duration of transgene expression in muscle tissues, overcoming the limitations of conventional single-element regulatory designs.
3Productivity
If muscle-specific promoters are used to enhance gene expression, then expression level in muscle is improved, but expression in unwanted cell types may occur
Solution Approach 1:
The patent segments the regulatory control into two distinct functional elements: a diaphragm-specific regulatory element (SEQ ID NO: 1) and a cardiac/skeletal muscle-specific regulatory element (SEQ ID NO: 2). Each element contributes to specificity for different muscle types, and their combination provides both high expression levels and refined tissue specificity, preventing expression in unwanted cell types while maintaining productivity in target muscles.
Data Source
AI summary
Nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly muscle-directed gene therapy.